<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pegylated liposomal doxorubicin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pegylated liposomal doxorubicin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pegylated liposomal doxorubicin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11357" href="/d/html/11357.html" rel="external">see "Pegylated liposomal doxorubicin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708687"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cardiomyopathy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Doxorubicin (liposomal) can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 and 550 mg/m<sup>2</sup>. Assess left ventricular cardiac function prior to initiation of doxorubicin (liposomal) and during and after treatment.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion-related reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, life-threatening, and fatal infusion-related reactions can occur with doxorubicin (liposomal). Acute infusion-related reactions occurred in 11% of patients with solid tumors. Withhold doxorubicin (liposomal) for infusion-related reactions and resume at a reduced rate. Discontinue doxorubicin (liposomal) for serious or life-threatening infusion-related reactions.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F15125198"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Doxil</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866672"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Caelyx;</li>
<li>TARO-Doxorubicin Liposomal</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F163273"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anthracycline;</li>
<li>
                        Antineoplastic Agent, Topoisomerase II Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F163255"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Liposomal formulations of doxorubicin should NOT be substituted for conventional doxorubicin hydrochloride on a mg-per-mg basis.</b> Medication and equipment to manage infusion reactions should be immediately available during infusion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="105cec0a-a7ca-40e2-861c-ca22d0bd524f">AIDS-related Kaposi sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>AIDS-related Kaposi sarcoma:</b>
<b>IV:</b> 20 mg/m<sup>2</sup> once every 21 days until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8423721-7a23-4fed-bf36-91a0c75f98e6">Breast cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic (off-label use):</b>
<b>IV:</b> 50 mg/m<sup>2</sup> every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15459210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15459210'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5393a755-28a8-4214-be54-2a791e58f47b">Castleman disease, multicentric, human herpesvirus-8-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Castleman disease, multicentric, human herpesvirus-8-associated (HHV-8 MCD) (off-label use): IV:</b> 20 mg/m<sup>2</sup> once every 3 weeks (in combination with rituximab and antiretroviral therapy); patients received up to 2 cycles beyond HHV-8 MCD symptom resolution and improvement in biochemical abnormalities and then received consolidation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25331113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25331113'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8dfcf241-b80d-43fd-b778-e776538bfd19">Cutaneous T-cell lymphomas, mycosis fungoides and Sézary syndrome, recurrent or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous T-cell lymphomas, mycosis fungoides and Sézary syndrome, recurrent or refractory (off-label use):</b>
<b>IV:</b> 20 mg/m<sup>2</sup> days 1 and 15 every 4 weeks for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23045580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23045580'])">Ref</a></span>) <b>or</b> 20 mg/m<sup>2</sup> every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12942567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12942567'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="52535998-e0f8-444b-8576-ed83a0805834">Diffuse large B-cell lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diffuse large B-cell lymphoma (off-label use): IV:</b> 30 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with cyclophosphamide, vincristine, and prednisone) for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12161358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12161358'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a665ed3b-09d9-4328-a37f-e025deecde71">Hodgkin lymphoma, salvage treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, salvage treatment (off-label use):</b> GVD regimen: <b>IV:</b> 15 mg/m<sup>2</sup> (10 mg/m<sup>2</sup> if post transplant) on days 1 and 8 every 3 weeks (in combination with gemcitabine and vinorelbine) for 2 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17426059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17426059'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4f575b1-9ab5-4ea5-b16e-1724f4fcbc62">Multiple myeloma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma: </b>
<b>IV:</b> 30 mg/m<sup>2</sup> on day 4 every 21 days (in combination with bortezomib) for 8 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17679727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17679727'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ca88c47-fed2-4025-88d5-3331e749f45f">Ovarian cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced:</b>
<b>IV:</b> 50 mg/m<sup>2</sup> once every 28 days until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV:</b> 30 mg/m<sup>2</sup> on day 1 every 28 days (in combination with bevacizumab and carboplatin) for up to 6 cycles, followed by bevacizumab maintenance; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32305099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32305099'])">Ref</a></span>) <b>or</b> 40 mg/m<sup>2</sup> once every 28 days (as a single agent) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18281662','lexi-content-ref-11531287']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18281662','lexi-content-ref-11531287'])">Ref</a></span>) <b>or</b> 30 mg/m<sup>2</sup> once every 28 days (in combination with carboplatin) for at least 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20498395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20498395'])">Ref</a></span>) <b>or </b>40 mg/m<sup>2</sup> once every 28 days (in combination with bevacizumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24637997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24637997'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce1aa2cf-df00-4185-90fa-2ea05cfe1e77">Soft tissue sarcoma, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcoma, advanced or metastatic (off-label use):</b>
<b>IV:</b> 50 mg/m<sup>2</sup> every 4 weeks for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11313175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11313175'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bacaa84-7082-4d05-81b4-a453bd881b77">Uterine leiomyosarcoma, advanced or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uterine leiomyosarcoma, advanced or recurrent (off-label use):</b>
<b>IV:</b> 50 mg/m<sup>2</sup> every 4 weeks until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15721421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15721421'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991577"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Dosage adjustment is not likely necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988751"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's US labeling. However, doxorubicin is predominantly hepatically eliminated and doxorubicin (liposomal) doses should be reduced in patients with serum bilirubin ≥1.2 mg/dL.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have also been recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Krens 2019:</p>
<p style="text-indent:-2em;margin-left:6em;">Bilirubin &gt;1.2 to &lt;3 mg/dL: Reduce dose to 75% of the original dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Bilirubin 3 to 5 mg/dL: Reduce dose to 50% of the original dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Bilirubin &gt;5 mg/dL: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Canadian labeling (Caelyx):</p>
<p style="text-indent:-2em;margin-left:6em;">Bilirubin 1.2 to 3 mg/dL: For patients with breast and ovarian cancers, reduce initial dose to 75% of normal dose; if tolerated and no increase in bilirubin/hepatic enzymes, may increase to full dose with cycle 2. For patients with AIDS-related Kaposi sarcoma, reduce dose to 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Bilirubin &gt;3 mg/dL: For patients with breast and ovarian cancers, reduce initial dose to 50% of normal dose; if tolerated and no increase in bilirubin/hepatic enzymes, may increase dose to 75% of normal dose for cycle 2; if cycle 2 dose tolerated, may increase to full dose for subsequent cycles. For patients with AIDS-related Kaposi sarcoma, reduce dose to 25% of normal dose.</p></div>
<div class="block doo drugH1Div" id="F20341646"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F163274"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Doxorubicin (Liposomal) Dosage Modification for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reactions </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Doxorubicin (liposomal)<sup>a,b</sup> dosage modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Once a dosage reduction due to toxicity has been implemented, the dose should not be increased at a later time.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Bortezomib may also require dosage modification; refer to Bortezomib monograph.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> HFS = hand foot syndrome.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;text-align:left;">HFS<sup>c</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1 (mild erythema, swelling, or desquamation not interfering with daily activities)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If no prior grade 3 or 4 HFS, no dosage adjustment is necessary. If prior grade 3 or 4 HFS, delay doxorubicin (liposomal) dose up to 2 weeks and then decrease dose by 25%.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2 (erythema, desquamation, or swelling interfering with, but not precluding normal physical activities; small blisters or ulcerations &lt;2 cm in diameter)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) dosing up to 2 weeks or until resolved to grade 0 or 1. If no resolution after 2 weeks, discontinue doxorubicin (liposomal). If resolved to grade 0 or 1 within 2 weeks AND no prior grade 3 or 4 HFS, continue treatment at previous dose. If resolved to grade 0 or 1 within 2 weeks AND prior grade 3 or 4 HFS has occurred, decrease dose by 25%.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 (blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) dosing up to 2 weeks or until resolved to grade 0 or 1, then decrease dose by 25%. If no resolution after 2 weeks, discontinue doxorubicin (liposomal).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 (diffuse or local process causing infectious complications, or a bedridden state or hospitalization)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) dosing up to 2 weeks or until resolved to grade 0 or 1, then decrease dose by 25%. If no resolution after 2 weeks, discontinue doxorubicin (liposomal).</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Infusion reaction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≤ grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Temporarily stop doxorubicin (liposomal) infusion until resolution and then resume at a reduced rate.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serious or life-threatening</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Discontinue doxorubicin (liposomal).</p></td></tr>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;text-align:left;">Stomatitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1 (painless ulcers, erythema, or mild soreness)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If no prior grade 3 or 4 toxicity, no dosage adjustment is necessary. If prior grade 3 or 4 toxicity, delay doxorubicin (liposomal) dose up to 2 weeks and then decrease dose by 25%.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2 (painful erythema, edema, or ulcers, but can eat)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) dosing up to 2 weeks or until resolved to grade 0 or 1. If no resolution after 2 weeks, discontinue doxorubicin (liposomal). If resolved to grade 0 or 1 within 2 weeks AND no prior grade 3 or 4 stomatitis, continue doxorubicin (liposomal) at previous dose. If resolved to grade 0 or 1 within 2 weeks AND prior grade 3 or 4 stomatitis, decrease doxorubicin (liposomal) dose by 25%.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 (painful erythema, edema, or ulcers, and cannot eat)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) dosing up to 2 weeks or until resolved to grade 0 or 1. Decrease dose by 25% and return to original dosing interval. If after 2 weeks there is no resolution, discontinue doxorubicin (liposomal).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 (requires parenteral or enteral support)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) dosing up to 2 weeks or until resolved to grade 0 or 1. Decrease dose by 25% and return to original dosing interval. If after 2 weeks there is no resolution, discontinue doxorubicin (liposomal).</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity: neutropenia or thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) until ANC ≥1,500/mm<sup>3</sup> and platelets ≥75,000/mm<sup>3</sup>; resume treatment at previous dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) until ANC ≥1,500/mm<sup>3</sup> and platelets ≥75,000/mm<sup>3</sup>; resume treatment at previous dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) until ANC ≥1,500/mm<sup>3</sup> and platelets ≥75,000/mm<sup>3</sup>; then resume with a 25% dose reduction or continue at previous dose with granulocyte growth factor support.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Doxorubicin (liposomal) dosage modification when administered in combination with bortezomib<sup>b</sup></b></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Fever ≥38°C and ANC &lt;1,000/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold doxorubicin (liposomal) for this cycle if prior to day 4. Decrease doxorubicin (liposomal) dose by 25% if after day 4 of previous cycle.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">On any day of doxorubicin (liposomal) administration after day 1 of each cycle:</p>
<ul>
<li>
<p style="text-indent:0em;">ANC &lt;500/mm<sup>3 </sup></p></li>
<li>
<p style="text-indent:0em;">Platelets &lt;25,000/mm<sup>3 </sup></p></li>
<li>
<p style="text-indent:0em;">Hemoglobin &lt;8 g/dL</p></li></ul></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold doxorubicin (liposomal) for this cycle if prior to day 4. Decrease doxorubicin (liposomal) dose by 25% if after day 4 of previous cycle AND if bortezomib dose is reduced for hematologic toxicity.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Nonhematologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neuropathic pain or peripheral neuropathy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No doxorubicin (liposomal) dose reduction is necessary. Refer to Bortezomib monograph for bortezomib dosing adjustment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4 nonhematologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) until recovered to &lt; grade 2, then reduce dose by 25%.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Canadian Labeling: Doxorubicin (Liposomal) Dosage Modification for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reactions </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Doxorubicin (liposomal) dosage modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Refer to Doxorubicin (Liposomal) Dosage Modification for Adverse Reactions table (above) for severity grade descriptions for PPE (see HFS above) and stomatitis.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>b</sup> PPE = Palmar-plantar erythrodysesthesia.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Breast cancer or ovarian cancer </b></p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">PPE<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If at weeks 4 and 5 following prior dose, resume dosing unless patient has experienced prior grade 3 or 4 PPE toxicity (if prior grade 3 or 4 PPE, wait an additional week).</p>
<p style="text-indent:0em;text-align:left;">If at week 6, decrease dose by 25%; return to 4-week interval.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If at weeks 4 and 5 following prior dose, wait an additional week.</p>
<p style="text-indent:0em;text-align:left;">If at week 6, decrease dose by 25%; return to 4-week interval.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3 or 4<sup>a</sup>
<i></i></p>
<p style="text-indent:0em;text-align:left;">
<i></i></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If at weeks 4 and 5 following prior dose, wait an additional week.</p>
<p style="text-indent:0em;text-align:left;">If at week 6, discontinue doxorubicin (liposomal).</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Stomatitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If at weeks 4 and 5 following prior dose, resume dosing unless patient has experienced prior grade 3 or 4 stomatitis (if prior grade 3 or 4 stomatitis, wait an additional week).</p>
<p style="text-indent:0em;text-align:left;">If at week 6, decrease dose by 25%; return to 4-week interval or discontinue doxorubicin (liposomal), based on assessment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If at weeks 4 and 5 following prior dose, wait an additional week.</p>
<p style="text-indent:0em;text-align:left;">If at week 6, decrease dose by 25%; return to 4-week interval or discontinue doxorubicin (liposomal), based on assessment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3 or 4<sup>a</sup></p>
<p style="text-indent:0em;text-align:left;">
<i></i></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If at weeks 4 and 5 following prior dose, wait an additional week.</p>
<p style="text-indent:0em;text-align:left;">If at week 6, discontinue doxorubicin (liposomal).</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity: neutropenia or thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 2 or 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) until ANC ≥1,500/mm<sup>3</sup> and platelets ≥75,000/mm<sup>3</sup>; resume treatment at previous dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) until ANC ≥1,500/mm<sup>3</sup> and platelets ≥75,000/mm<sup>3</sup>; then resume with a 25% dose reduction or continue at previous dose with granulocyte growth factor support.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>AIDS-related Kaposi sarcoma</b></p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">PPE</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If at week 3 following prior dose, resume unless prior grade 3 or 4 PPE toxicity (if prior grade 3 or 4 PPE, wait an additional week).</p>
<p style="text-indent:0em;text-align:left;">If at week 4 following prior dose, decrease dose by 25% and return to 3-week interval.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If at week 3 following prior dose, wait an additional week.</p>
<p style="text-indent:0em;text-align:left;">If at week 4 following prior dose, decrease dose by 50% and return to 3-week interval</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3 or 4<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If at week 3 following prior dose, wait an additional week.</p>
<p style="text-indent:0em;text-align:left;">If at week 4, discontinue doxorubicin (liposomal).</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Stomatitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Wait 1 week and if symptoms improve, resume at 100% dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Wait 1 week and if symptoms improve, resume with a 25% dose reduction.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Wait 1 week and if symptoms improve, resume with a 50% dose reduction.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity: neutropenia or thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) until ANC ≥1,000/mm<sup>3</sup> and/or platelets ≥50,000/mm<sup>3</sup> and then resume with a 25% dose reduction.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Delay doxorubicin (liposomal) until ANC ≥1,000/mm<sup>3</sup> and/or platelets ≥50,000/mm<sup>3</sup> and then resume with a 50% dose reduction.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F163256"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F163221"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (&gt;20%), headache (1% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Palmar-plantar erythrodysesthesia (ovarian cancer: 51%), skin rash (ovarian cancer: 29%, Kaposi sarcoma: 1% to 5%), alopecia (ovarian cancer: 19%; Kaposi sarcoma: 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (ovarian cancer: 46%; Kaposi sarcoma: 17%), stomatitis (ovarian cancer: 41%; ovarian cancer, grades 3/4: 8%: Kaposi sarcoma: 7%), vomiting (ovarian cancer: 33%; Kaposi sarcoma: 8%), diarrhea (ovarian cancer: 21%; Kaposi sarcoma: 8%), constipation (&gt;20%), anorexia (20%; Kaposi sarcoma: 1% to 5%), mucous membrane disease (ovarian cancer: 14%), dyspepsia (ovarian cancer: 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (Kaposi sarcoma: grade 3: 61%, grade 4: 4%; ovarian cancer: grade 3: 1%), anemia (Kaposi sarcoma: grade 3: 55%, grade 4: 18%; grade 3: 5%, grade 4: &lt;1%), neutropenia (Kaposi sarcoma: grade 3: 49%, grade 4: 13%; ovarian cancer: grade 3: 8%, grade 4: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (1% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (ovarian cancer: 40%; Kaposi sarcoma: 10%), back pain (1% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (ovarian cancer: 16%; Kaposi sarcoma: &lt;1%), dyspnea (ovarian cancer: 15%; Kaposi sarcoma: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (ovarian cancer: 21%; Kaposi sarcoma: 9%), infusion related reaction (7% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombosis (ovarian cancer: 1% to 10%), hypotension (1% to 10%), tachycardia (1% to 10%), vasodilation (ovarian cancer: 1% to 10%), chest pain (1% to 5%), peripheral edema (ovarian cancer: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Depression (ovarian cancer: 1% to 10%), dizziness (1% to 10%), drowsiness (1% to 10%), anxiety (ovarian cancer: 1% to 5%), chills (1% to 5%), emotional lability (Kaposi sarcoma: 1% to 5%), insomnia (ovarian cancer: 1% to 5%), malaise (ovarian cancer: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (ovarian cancer: 1% to 10%), ecchymoses (ovarian cancer: 1% to 10%), exfoliative dermatitis (ovarian cancer: 1% to 10%), fungal dermatitis (ovarian cancer: 1% to 10%), furunculosis (ovarian cancer: 1% to 10%), herpes simplex dermatitis (1% to 10%), maculopapular rash (ovarian cancer: 1% to 10%; Kaposi sarcoma: &lt;1%), pruritus (1% to 10%), skin discoloration (ovarian cancer: 1% to 10%), vesiculobullous dermatitis (ovarian cancer: 1% to 10%), xeroderma (ovarian cancer: 1% to 10%), diaphoresis (ovarian cancer: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (ovarian cancer: 1% to 10%; Kaposi sarcoma: &lt;1%), hypercalcemia (ovarian cancer: 1% to 10%), hypokalemia (ovarian cancer: 1% to 10%), hyponatremia (ovarian cancer: 1% to 10%), weight loss (1% to 10%), albuminuria (Kaposi sarcoma: 1% to 5%), hyperglycemia (Kaposi sarcoma: 1% to 5%), hypocalcemia (Kaposi sarcoma: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (ovarian cancer: 1% to 10%; Kaposi sarcoma: &lt;1%), dysphagia (1% to 10%), esophagitis (ovarian cancer: 1% to 10%), intestinal obstruction (ovarian cancer: 1% to 10%), oral candidiasis (1% to 10%), oral mucosa ulcer (1% to 10%), abdominal pain (Kaposi sarcoma: 1% to 5%), aphthous stomatitis (Kaposi sarcoma: 1% to 5%), enlargement of abdomen (ovarian cancer 1% to 5%), glossitis (Kaposi sarcoma: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (ovarian cancer: 1% to 10%), urinary tract infection (ovarian cancer: 1% to 10%), vulvovaginal candidiasis (ovarian cancer: 1% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Rectal hemorrhage (ovarian cancer: 1% to 10%), hypochromic anemia (Kaposi sarcoma: ≥5%), hemolysis (Kaposi sarcoma: 1% to 5%), prolonged prothrombin time (Kaposi sarcoma: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (1% to 10%), increased serum alkaline phosphatase (Kaposi sarcoma: 8%), increased serum alanine aminotransferase (Kaposi sarcoma: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (ovarian cancer: 1% to 10%; Kaposi sarcoma: &lt;1%), paresthesia (5%), myalgia (ovarian cancer: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (ovarian cancer: 1% to 10%; Kaposi sarcoma: &lt;1%), dry eye syndrome (ovarian cancer: 1% to 10%), retinitis (Kaposi sarcoma 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Increased cough (ovarian cancer: 10%; Kaposi sarcoma: &lt;1%), epistaxis (ovarian cancer: 1% to 10%), pneumonia (1% to 10%), rhinitis (ovarian cancer: 1% to 10%), sinusitis (ovarian cancer: 1% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Bundle branch block, candidiasis, cardiac failure, cryptococcosis, hepatitis, palpitations, sepsis, thrombophlebitis, thrombosis, ventricular arrhythmia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression, progression of cancer</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Toxoplasmosis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Erythema multiforme, lichenoid eruption (keratosis), muscle spasm, pulmonary embolism, secondary acute myelocytic leukemia, squamous cell carcinoma, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>
<div class="block coi drugH1Div" id="F163235"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of severe hypersensitivity (including anaphylaxis) to doxorubicin (liposomal), conventional doxorubicin, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Breastfeeding.</p></div>
<div class="block war drugH1Div" id="F163218"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Neutropenia, anemia, and thrombocytopenia may occur. Hematologic toxicity may occur at a higher frequency and severity with combination chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiomyopathy: Doxorubicin (liposomal) can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 and 550 mg/m<sup>2</sup>. Cardiomyopathy is defined as a &gt;20% decrease in resting left ventricular ejection fraction (LVEF) from baseline (if LVEF remained in the normal range) or a &gt;10% decrease from baseline (where LVEF was less than the institutional lower limit of normal). Some patients developed signs/symptoms of heart failure without documented evidence of cardiomyopathy. The risk of cardiomyopathy with doxorubicin is generally proportional to the cumulative exposure; include prior use of other anthracyclines or anthracenediones in the calculations of the cumulative dose. The risk of cardiomyopathy may be increased at lower cumulative doses in patients with prior mediastinal irradiation. Use in patients with a history of cardiovascular disease only if potential benefits outweigh cardiovascular risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: Serious, life-threatening, and fatal infusion-related reactions can occur with doxorubicin (liposomal). Acute infusion-related reactions occurred in 11% of patients with solid tumors. Infusion reactions may include flushing, shortness of breath, facial swelling, headache, chills, back pain, tightness in the chest or throat, fever, hypotension, chest pain, pruritus, rash, cyanosis, syncope, tachycardia, bronchospasm, asthma, and apnea. Most reactions occurred during the first infusion. Some reactions have resulted in dose interruption.</p>
<p style="text-indent:-2em;margin-left:4em;">• Palmar-plantar erythrodysesthesia (hand-foot syndrome): Hand-foot syndrome has been reported in patients receiving doxorubicin (liposomal), including grade 3 or 4 cases. It is usually seen after 2 to 3 treatment cycles, although may also occur earlier.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Cases of secondary oral cancers (primarily squamous cell carcinoma) have been reported with long-term (&gt;1 year) doxorubicin (liposomal) exposure; these secondary oral malignancies have occurred during treatment and up to 6 years after treatment. The development of oral ulceration or discomfort should be monitored and further evaluated in patients with past or present use of doxorubicin (liposomal). Tissue distribution of the liposomal doxorubicin compared to free doxorubicin may play a role in the development of oral secondary malignancies associated with long-term use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Liposomal vs conventional formulation dosing: Liposomal formulations of doxorubicin should <b>NOT</b> be substituted for conventional doxorubicin hydrochloride on a mg-per-mg basis.</p></div>
<div class="block dosfc drugH1Div" id="F46098831"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Doxil, generic doxorubicin HCl liposomal (Sun Pharma), and Caelyx (Canadian product) are pegylated liposomal formulations of doxorubicin hydrochloride.</p></div>
<div class="block foc drugH1Div" id="F163229"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Doxil: 2 mg/mL (10 mL, 25 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (10 mL, 25 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (10 mL, 25 mL)</p></div>
<div class="block geq drugH1Div" id="F163214"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323123"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Injection</b> (Doxil Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $79.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Injection</b> (DOXOrubicin HCl Liposomal Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $54.00 - $116.28</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866673"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Caelyx: 2 mg/mL (10 mL) [contains phosphatidylcholine, soy]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (10 mL, 25 mL)</p></div>
<div class="block adm drugH1Div" id="F163232"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> For IV infusion only; do not administer IV push. If contact with skin/mucosa occurs, wash immediately with soap and water. Monitor for infusion reaction. Medication and equipment to manage infusion reactions should be immediately available during infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Administer IVPB over 60 minutes; the manufacturer recommends infusing the first dose at initial rate of 1 mg/minute to minimize risk of infusion reactions; if no infusion-related reactions are observed, then increase the infusion rate for completion over 1 hour. Do <b>NOT</b> administer undiluted. Do <b>NOT</b> infuse with in-line filters. Do not mix with other medications. Monitor for local erythematous streaking along vein and/or facial flushing (may indicate rapid infusion rate).</p>
<p style="text-indent:-2em;margin-left:4em;">For multiple myeloma, administer doxorubicin (liposomal) after bortezomib on day 4 of each cycle.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Irritant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>); monitor infusion site; avoid extravasation. Assure proper needle or catheter position prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation, infiltration, or burning/stinging sensation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449','lexi-content-ref-Polovich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449','lexi-content-ref-Polovich.1'])">Ref</a></span>). Do not apply pressure to the site. Apply ice to the site for 15 minutes 4 times a day for 3 days.</p></div>
<div class="block hazard drugH1Div" id="F49130977"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F163230"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>AIDS-related Kaposi sarcoma:</b> Treatment of AIDS-related Kaposi sarcoma after failure of or intolerance to prior systemic therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma:</b> Treatment of multiple myeloma (in combination with bortezomib) in patients who have not previously received bortezomib and have received at least 1 prior therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced:</b> Treatment of ovarian cancer after progression or recurrence on platinum-based chemotherapy.</p></div>
<div class="block off-label drugH1Div" id="F25474922"><span class="drugH1">Use: Off-Label: Adult</span><p>Breast cancer, metastatic; Castleman disease, multicentric (human herpesvirus-8-associated); Cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome), recurrent or refractory; Diffuse large B-cell lymphoma; Hodgkin lymphoma (salvage treatment); Soft tissue sarcomas, advanced or metastatic; Uterine leiomyosarcoma, advanced or recurrent</p></div>
<div class="block mst drugH1Div" id="F163282"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Liposomal formulation (Doxil) may be confused with the conventional formulation (Adriamycin)</p>
<p style="text-indent:-2em;margin-left:4em;">DOXOrubicin liposomal may be confused with DACTINomycin, DAUNOrubicin, DAUNOrubicin liposomal, daunorubicin/cytarabine (liposomal), doxapram, doxazosin, DOXOrubicin (conventional), epiRUBicin, IDArubicin, valrubicin</p>
<p style="text-indent:-2em;margin-left:4em;">Doxil may be confused with Doxy 100, Paxil</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Use caution when selecting product for preparation and dispensing; indications, dosages, rate of administration, and adverse event profiles differ between conventional DOXOrubicin hydrochloride solution and DOXOrubicin liposomal. Both formulations are the same concentration. As a result, serious errors have occurred. Liposomal formulation of doxorubicin should NOT be substituted for doxorubicin hydrochloride on a mg-per-mg basis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Caelyx [Canada] may be confused with Myocet [Canada]; product formulations and indications differ</p>
<p style="text-indent:-2em;margin-left:4em;">Doxil [US, Israel] may be confused with Doxal brand name for doxepin [Finland] and pyridoxine/thiamine [Brazil]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F163268"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F163223"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ado-Trastuzumab Emtansine: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with ado-trastuzumab emtansine should avoid anthracycline-based therapy for up to 7 months after stopping ado-trastuzumab emtansine.  Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bevacizumab: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of DOXOrubicin (Liposomal).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fam-Trastuzumab Deruxtecan: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with fam-trastuzumab deruxtecan should avoid anthracycline-based therapy for up to 7 months after stopping fam-trastuzumab deruxtecan. Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Margetuximab: Anthracyclines may enhance the adverse/toxic effect of Margetuximab. Specifically, the risk of cardiac dysfunction may be increased.  Management: Avoid anthracycline-based therapy for up to 4 months after discontinuing margetuximab due to an increased risk of cardiac dysfunction. If anthracyclines must be used with margetuximab monitor cardiac function closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: May diminish the therapeutic effect of PEGylated Drug Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvaliase: PEGylated Drug Products may enhance the adverse/toxic effect of Pegvaliase. Specifically, the risk of anaphylaxis or hypersensitivity reactions may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of DOXOrubicin (Liposomal).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stavudine: DOXOrubicin (Liposomal) may diminish the therapeutic effect of Stavudine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taxane Derivatives: May enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue. Management: Consider separating doxorubicin and paclitaxel administration by as much time as possible, using liposomal doxorubicin or epirubicin instead of doxorubicin, or using docetaxel instead of paclitaxel. Monitor closely for cardiovascular and other toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trastuzumab: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab.  Monitor closely for cardiac dysfunction in patients receiving anthracyclines with trastuzumab.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: DOXOrubicin (Liposomal) may enhance the adverse/toxic effect of Vinflunine. Specifically, the risk for hematologic toxicities may be increased. DOXOrubicin (Liposomal) may increase the serum concentration of Vinflunine. Vinflunine may decrease the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: DOXOrubicin (Liposomal) may enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Liposomal) may diminish the therapeutic effect of Zidovudine.  Management: Avoid concomitant use of doxorubicin and zidovudine. Reduced efficacy of zidovudine is possible based on in vitro data. Also, increased myelosuppressive effects are possible with combined administration.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49298502"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant and patients with partners who could become pregnant should use effective contraception during therapy and for 6 months after doxorubicin (liposomal) treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Doxorubicin (liposomal) may impair fertility. Doxorubicin (liposomal) may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities; may also result in oligospermia, azoospermia, and permanent loss of fertility (sperm counts have been reported to return to normal levels in some patients, occurring several years after the end of therapy). Doxorubicin (liposomal) may cause amenorrhea and infertility. Premature menopause can occur; return of menses and ovulation may be related to age at treatment.</p></div>
<div class="block pri drugH1Div" id="F163237"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In placental perfusion studies, doxorubicin (liposomal) crossed the placenta similar to conventional doxorubicin (Soininen 2015). Based on the mechanism of action and data from animal reproduction studies, in utero exposure to doxorubicin (liposomal) may cause fetal harm. Doxorubicin (liposomal) use during the first trimester should be avoided.</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry, or to become a participant, contact Cooper Health (1-877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F5045756"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if doxorubicin (liposomal) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding should be discontinued during doxorubicin (liposomal) treatment.</p></div>
<div class="block mop drugH1Div" id="F163227"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelet count, liver function tests (ALT/AST, bilirubin, alkaline phosphatase). Assess left ventricular function with ECG or multigated acquisition scan prior to and during treatment to detect acute changes; monitor after treatment to detect delayed cardiotoxicity. Verify pregnancy status prior to treatment initiation (in patients who could become pregnant). Monitor infusion site. Monitor for infusion reactions, hand-foot syndrome, stomatitis, and oral ulceration/discomfort suggestive of secondary oral malignancy.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F163217"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Doxorubicin inhibits DNA and RNA synthesis by intercalating between DNA base pairs causing steric obstruction and inhibits topoisomerase-II at the point of DNA cleavage. Doxorubicin is also a powerful iron chelator. The iron-doxorubicin complex can bind DNA and cell membranes, producing free hydroxyl (OH) radicals that cleave DNA and cell membranes. Doxorubicin (liposomal) is a pegylated formulation which protects the liposomes, and thereby increases blood circulation time.</p></div>
<div class="block phk drugH1Div" id="F163234"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>dss</sub>: ~2.7 to 2.8 L/m<sup>2</sup>; largely confined to vascular fluid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding, plasma: Unknown; nonliposomal (conventional) doxorubicin: ~70%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: Distribution: ~4.7 to 5.2 hours, Elimination: ~52 to 55 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic and in plasma to doxorubicinol and the sulfate and glucuronide conjugates of 4-demethyl,7-deoxyaglycones </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F163238"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Doxil | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adrisome | Caelyx | Lipo dox | Lippod | Natdox lp | Pegadria</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Doxil</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bdlypo | Caelyx</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx | Zolsketil pegylated liposomal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Caelyx</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17426059">
<a name="17426059"></a>Bartlett NL, Niedzwiecki D, Johnson JL, et al; Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. <i>Ann Oncol</i>. 2007;18(6):1071-1079. doi:10.1093/annonc/mdm090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/17426059/pubmed" id="17426059" target="_blank">17426059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caelyx.1">
<a name="Caelyx.1"></a>Caelyx (doxorubicin hydrochloride [pegylated liposomal]) [product monograph]. Mississauga, Ontario, Canada: Baxter Corporation; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doxil.1">
<a name="Doxil.1"></a>Doxil (doxorubicin [liposomal]) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sun.1">
<a name="Sun.1"></a>Doxorubicin Hydrochloride (liposomal) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23045580">
<a name="23045580"></a>Dummer R, Quaglino P, Becker JC, Hasan B, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. <i>J Clin Oncol</i>. 2012;30(33):4091-4097. doi:10.1200/JCO.2011.39.8065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/23045580/pubmed" id="23045580" target="_blank">23045580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18281662">
<a name="18281662"></a>Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. <i>J Clin Oncol</i>. 2008;26(6):890-896. doi:10.1200/JCO.2007.13.6606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/18281662/pubmed" id="18281662" target="_blank">18281662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11454878">
<a name="11454878"></a>Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. <i>J Clin Oncol</i>. 2001;19(14):3312-3322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/11454878/pubmed" id="11454878" target="_blank">11454878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10963637">
<a name="10963637"></a>Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. <i>J Clin Oncol</i>. 2000;18(17):3093-3100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/10963637/pubmed" id="10963637" target="_blank">10963637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11313175">
<a name="11313175"></a>Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. <i>Eur J Cancer</i>. 2001;37(7):870-877. doi:10.1016/s0959-8049(01)00050-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/11313175/pubmed" id="11313175" target="_blank">11313175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15459210">
<a name="15459210"></a>Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. <i>J Clin Oncol</i>. 2004;22(19):3893-3901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/15459210/pubmed" id="15459210" target="_blank">15459210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12161358">
<a name="12161358"></a>Martino R, Perea G, Caballero MD, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine, and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. <i>Haematologica</i>. 2002;87(8):822-827.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/12161358/pubmed" id="12161358" target="_blank">12161358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9667262">
<a name="9667262"></a>Northfelt DW, Dezebe BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. <i>J Clin Oncol</i>. 1998;16(7):2445-2451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/9667262/pubmed" id="9667262" target="_blank">9667262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4998846">
<a name="4998846"></a>O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. <i>Ann Oncol</i>. 2004;15(3):440-449.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/4998846/pubmed" id="4998846" target="_blank">4998846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17679727">
<a name="17679727"></a>Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. <i>J Clin Oncol</i>. 2007;25(25):3892-3901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/17679727/pubmed" id="17679727" target="_blank">17679727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(Suppl 7):167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32305099">
<a name="32305099"></a>Pfisterer J, Shannon CM, Baumann K, et al; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2020;21(5):699-709. doi:10.1016/S1470-2045(20)30142-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/32305099/pubmed" id="32305099" target="_blank">32305099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polovich.1">
<a name="Polovich.1"></a>Polovich M, Whitford JN, Olsen M. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice, 3rd ed. Pittsburgh, PA: Oncology Nursing Society; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24637997">
<a name="24637997"></a>Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. <i>J Clin Oncol</i>. 2014;32(13):1302-1308. doi:10.1200/JCO.2013.51.4489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/24637997/pubmed" id="24637997" target="_blank">24637997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20498395">
<a name="20498395"></a>Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. <i>J Clin Oncol</i>. 2010;28(20):3323-3329. doi:10.1200/JCO.2009.25.7519<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/20498395/pubmed" id="20498395" target="_blank">20498395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11531287">
<a name="11531287"></a>Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. <i>Gynecol Oncol</i>. 2001;82(2):323-328. doi:10.1006/gyno.2001.6272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/11531287/pubmed" id="11531287" target="_blank">11531287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24504445">
<a name="24504445"></a>Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, et al, A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. <i>Ann Oncol</i>. 2014 Mar;25(3):599-605.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/24504445/pubmed" id="24504445" target="_blank">24504445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26383631">
<a name="26383631"></a>Soininen SK, Repo JK, Karttunen V, Auriola S, Vähäkangas KH, Ruponen M. Human placental cell and tissue uptake of doxorubicin and its liposomal formulations. <i>Toxicol Lett</i>. 2015;239(2):108-114. doi:10.1016/j.toxlet.2015.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/26383631/pubmed" id="26383631" target="_blank">26383631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19687336">
<a name="19687336"></a>Sparano JA, Makhson AN, Semiglazov VF, et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study. <i>J Clin Oncol</i>. 2009;27(27):4522-4529.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/19687336/pubmed" id="19687336" target="_blank">19687336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15721421">
<a name="15721421"></a>Sutton G, Blessing J, Hanjani P, et al. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. <i>Gynecol Oncol</i>. 2005;96(3):749-752.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/15721421/pubmed" id="15721421" target="_blank">15721421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25331113">
<a name="25331113"></a>Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. <i>Blood</i>. 2014;124(24):3544-3552. doi:10.1182/blood-2014-07-586800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/25331113/pubmed" id="25331113" target="_blank">25331113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed September 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12942567">
<a name="12942567"></a>Wollina U, Dummer R, Brockmeyer NH. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. <i>Cancer</i>. 2003;98(5):993-1001. doi:10.1002/cncr.11593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-liposomal-doxorubicin-drug-information/abstract-text/12942567/pubmed" id="12942567" target="_blank">12942567</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10135 Version 389.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
